



# The Promise of Clinical Trials: Transforming Tomorrow's Health

**SCRI Clinical Trials Symposium 2024**

**30 – 31 Jul 2024 • Raffles City Convention Centre**



## Our Sponsors and Partners

### Gold Sponsor



### Silver Sponsor



### Bronze Sponsor



### Healthcare Cluster Partners





# Contents

|                                                       |    |
|-------------------------------------------------------|----|
| SCRI Clinical Trials Symposium 2024                   | 04 |
| About SCRI                                            | 05 |
| Event Floorplan                                       | 06 |
| Day 1 Programme                                       | 07 |
| Day 2 Programme                                       | 11 |
| The Value Proposition of Clinical Trials in Singapore | 15 |

# SCRI Clinical Trials Symposium 2024

The SCRI Clinical Trials Symposium 2024 is themed “The Promise of Clinical Trials: Transforming Tomorrow’s Health” and brings together clinicians, researchers, academics, and industry experts in clinical research from around the world. The Symposium will offer an excellent opportunity for knowledge exchange and networking, share practical insights of how clinical trials improve patients’ lives and contribute towards positive health and economic outcomes in Singapore and beyond.



## Event Highlights

The two-day event will discuss:

- The value proposition of clinical trials in Singapore
- The importance of health economic outcomes research
- How real world-data complements traditional clinical development approaches
- Conduct of decentralised clinical trials
- Patient advocacy in clinical trials design

## What You Can Expect



**10**

Thought Leadership  
Topics



**40+**

Academic &  
Industry Partners



**45+**

Senior Clinical  
Trialists & Regulatory  
Heads



**500+**

Attendees

## About SCRI



SCRI was established in 2008 as the national academic clinical research organisation to enhance the standards of clinical research in Singapore by developing core capabilities, infrastructure and scientific leadership for clinical research.

In 2021, SCRI was appointed as the national coordinating body to implement the national clinical trial strategy and enhance Singapore's clinical trial ecosystem.

This is accomplished through the deployment of innovative technologies and processes, and strategic coordination of ecosystem capabilities and infrastructure to achieve synergies that will enhance the clinical research ecosystem aimed towards a healthier community and better patient outcomes.

### SCRI's key pillars include:



Clinical Research  
Operations



Academic Research  
Partnerships



Clinical Research  
Networks




SCRI Academy


SCRI is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS). SCRI is supported by the Singapore Ministry of Health through the NMRC Office, MOH Holdings Pte Ltd under the NMRC Enablers and Infrastructure Support for Clinical Trials-related Activities funding initiative (MOH-001144).

## Day 1 • Event Floorplan

Morning




Afternoon




## Day 2 • Event Floorplan

Morning



Afternoon



# 30 July 2024, Tuesday • Day 1 Programme

08:00 – 09:00 Registration and Breakfast

09:00 – 09:10 Welcome & Introduction

Main Plenary Room



**Prof John Lim**

Chairman, Consortium for Clinical Research and Innovation, Singapore (CRIS)  
Senior Advisor, Ministry of Health (MOH)  
Executive Director, Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School

09:10 – 09:25 Guest of Honour – Opening Address

Main Plenary Room



**Mr Heng Swee Keat**

Deputy Prime Minister & Chairman  
National Research Foundation

09:25 – 10:00 The Value Proposition of Clinical Trials and  
The Official Launch of Centralised Clinical Trials Portal  
*The Value Proposition of Clinical Trials*

Main Plenary Room



**Adj A/Prof Danny Soon**

CEO, Consortium for Clinical Research and Innovation, Singapore (CRIS)  
Executive Director, SCRI

10:00 – 10:30 Keynote Address 1  
*How Clinical Trials Underpinned Our Global Response to the COVID Pandemic*

Main Plenary Room



**Sir Jeremy Farrar**

Chief Scientist  
World Health Organization (WHO)

10:30 – 11:00 Keynote Address 2  
*How Clinical Trials Can Play a Role in Transforming the Singapore Healthcare System*

Main Plenary Room



**Prof Kenneth Mak**

Director-General of Health  
Ministry of Health (MOH), Singapore

# 30 July 2024, Tuesday • Day 1 Programme

11:00 – 11:45

Main Plenary  
Room

Panel Discussion

*Clinical Trials – Value Proposition from the Patient's,  
Healthcare and Industry Perspective*



**Prof Kenneth Mak**

Director-General of Health  
Ministry of Health (MOH), Singapore



**Dr Daphne Gardner**

Senior Consultant Endocrinologist  
Singapore General Hospital (SGH)



**Ms Poh Hwee Tee**

Country President  
Novartis Singapore and  
Asian Emerging Markets



**A/Prof David Tan**

Senior Consultant Medical Oncologist,  
National University Cancer Institute, Singapore (NCIS)  
Associate Professor,  
NUS Yong Loo Lin School of Medicine  
Head, Innovation Transfer Office (Research Office),  
National University Health System (NUHS)



**Mr Adrian Yap**

NASH Patient



**Adj A/Prof Danny Soon**

CEO, Consortium for Clinical Research  
and Innovation, Singapore (CRIS)  
Executive Director, SCRI

MODERATOR

11:45 – 13:15

Lunch & Networking

13:15 – 14:45

Breakout  
Room A

Track 1: Health Economics and Outcomes Research (HEOR)

*Clinical Trials for Health Outcomes and Its Impact on Healthcare*

Health Economics and Outcomes Research (HEOR) aims to understand the value of healthcare interventions by examining their cost-effectiveness, cost-benefit ratio, and its overall impact on population health.

Find out how clinical trials for health outcomes seek to improve the health outcomes of patients, optimise healthcare systems and ensure the cost-efficient use of resources.



**Prof David Matchar**

Professor & Inaugural Director  
(2008–2018)  
Health Services and Systems  
Signature Research Programme  
Duke–NUS Medical School



**Adj Asst Prof Oh Hong Choon**

Deputy Director, Health Services Research,  
Changi General Hospital  
Deputy Director, Centre for Population Health  
Research & Implementation, SingHealth  
Adjunct Assistant Professor,  
Duke–NUS Graduate Medical School  
Adjunct Senior Fellow, SUTD Academy



**Adj Prof Kelvin Bryan Tan**

Principal Health Economist Chief  
Health Economist's Office,  
Ministry of Health (MOH)



**A/Prof Edwin Chan**

Director, Cochrane Singapore  
Associate Professor,  
Duke–NUS Medical School  
Chief Scientific Officer, SCRI

MODERATOR

# 30 July 2024, Tuesday • Day 1 Programme

13:15 – 14:45

Breakout  
Room B

## Track 2: Industry Sponsored Track (By Takeda) *From Theory to Practice, Trials and Tribulations in Singapore*

There are numerous factors influencing clinical trial site selection. In this track, experts from industry, academia and public health will delve into the suitability of choosing Singapore as a clinical trial site and address some of the unique challenges faced. Using dengue trials as case studies, the session will illustrate these points and contextualise Singapore's role in the global clinical trial landscape.



### Dr Chia Po Ying

Head, NCID Research Office  
Consultant, NCID and Tan Tock Seng Hospital  
Assistant Professor,  
Lee Kong Chian School of Medicine



### Ms Lara Grace Gonzales Marzo

Associate Director and Therapeutic  
Area Lead  
Takeda Development Centre (TDC)  
Singapore Clinical Operations



### Prof Jenny Low

Co-Director, Viral Research and Experimental  
Medicine Centre, SingHealth Duke-NUS AMC  
Deputy Clinical and Scientific Director,  
SingHealth Investigational Medicine Unit  
Senior Consultant, Department of Infectious  
Diseases, Singapore General Hospital  
Professor, Programme in Emerging Infectious  
Diseases, Duke-NUS Medical School



### Prof Hsu Li Yang

Vice Dean (Global Health), Programme Leader  
(Infectious Diseases) and Professor, NUS Saw  
Swee Hock School of Public Health (Primary)  
Professor, NUS Yong Loo Lin School of Medicine (Joint)  
Associate Director, NUS Singapore Centre for  
Environmental Life Sciences Engineering  
Visiting Consultant, St Luke's Hospital  
Visiting Consultant, Ang Mo Kio Community Hospital  
Adjunct Clinician-Scientist, NanoBio Lab, A\*STAR

MODERATOR

14:45 – 15:15

Tea Break

15:15 – 16:45

Breakout  
Room A

## Track 3: Patient Advocacy and Community Engagement *Patient Advocacy Groups, Community Involvement and Collaboration in Advancing Clinical Research*

Patient advocacy groups and community engagement now play a more significant role in clinical research. Find out how these collaborations encourage a deeper understanding of patient needs, sharpens research relevance, and accelerates the development of innovative therapies for better healthcare.



### Ms Alison Evans

CEO  
Australia New Zealand  
Gynaecological Oncology Group  
(ANZGOG)



### Dr Nikki Kitikiti

Vaccines External Engagement Lead,  
Takeda Pharmaceuticals International  
Associate Visiting Expert,  
Centre of Regulatory Excellence,  
Duke-NUS Medical School



### Ms Nidhi Swarup

Founding Chair  
Alliance of Patients' Organizations  
Singapore Ltd



### Ms Ai Ling Sim-Devadas

Deputy Director,  
Office of Patient Engagement (OPEN)  
Lee Kong Chian School of Medicine,  
Nanyang Technological University (NTU)

MODERATOR

# 30 July 2024, Tuesday • Day 1 Programme

15:15 – 16:45

**Breakout  
Room B**

## Track 4: Decentralised Clinical Trials *Benefits and Challenges of DCTs*

Decentralised clinical trials have transformed the conduct of clinical trials by offering increased accessibility and flexibility for participants. In this session, hear more on how digital technologies and patient-centric approaches have enhanced patient engagement, reduced physical limitations, and accelerated the progress of decentralised clinical trials.



**Ms Veronika Brandmair**

E-Clinical Solutions Specialist  
Quadratek Data Solutions Ltd.



**Dr Pramod Kashid**

CEO  
Expecto Health Science



**Prof Derek Hausenloy**

Executive Director,  
Cardiovascular Disease National  
Collaborative Enterprise (CADENCE)

Research Director and Senior Consultant  
Cardiologist, National Heart Research  
Institute, National Heart Centre Singapore

Professor (Signature Research Program  
in Cardiovascular & Metabolic Disorders),  
Duke-NUS Medical School



**Mr Henning Lux**

CEO  
Quadratek Data Solutions Ltd.



**Ms Serene Ong**

Founder  
Phoenixus

**MODERATOR**

16:45

**End of Day 1**

\*Please note that the programme may be subject to change without prior notice. Tracks 1-10 will comprise of a 45-min presentation by speakers followed by 45-min panel discussion.

# 31 July 2024, Wednesday • Day 2 Programme

08:00 – 09:00 Registration

## 09:00 – 10:30 Track 5: Adaptive Trial Design (Complex Clinical Trial Design) *Lessons Learned and Best Practices – Adaptive Trial Design*

Breakout  
Room A

Delve into the lessons learned and best practices in navigating complex trial design for clinical trials. This session will discuss how adaptive clinical trial designs can enhance efficiency in clinical research.



### Prof David Lye

Director,  
Infectious Disease Research and  
Training Office, National Centre for  
Infectious Disease (NCID)  
  
Deputy Executive Director,  
Programme for Research in Epidemic  
Preparedness and Response (PREPARE)  
  
Professor,  
Lee Kong Chian School of Medicine,  
NTU & NUS Yong Loo Lin School of Medicine



### A/Prof Julie Marsh

Biostatistician  
Telethon Kids Institute and University of  
Western Australia Medical School



### Dr Venkateshan Srirangam

Medical Director  
Experimental Drug Development Centre  
(EDDC)



### Dr Mihir Gandhi

Head, Biostatistics  
SCRI

MODERATOR

## 09:00 – 10:30 Track 6: Trends in Clinical Trials *Unveiling Diverse Clinical Trial Landscapes Across Countries*

Breakout  
Room B

Many countries see clinical trials as essential to their health systems, and driving economic value capture. In this session, our international panel of speakers will share the various initiatives their countries have put in place to attract and grow clinical trials.



### Ms Marianne Pilgaard

CEO  
Trial Nation, Denmark



### Ms Indri Rooslamiati Supriadi

Acting Director, National Biomedical  
Genome and Science Institute  
Ministry of Health, Indonesia



### Mr Henry Yau

CEO, University of Hong Kong  
Clinical Trials Centre (China)  
  
Managing Director,  
University of Hong Kong Clinical  
Trials Centre (China)  
  
Honorary Assistant Professor,  
Macau University of Science  
and Technology



### Dr Akhmal Yusof

CEO  
Clinical Research Malaysia



### Ms Evelyn Pang

General Manager  
Moderna Biotech Singapore

MODERATOR

# 31 July 2024, Wednesday • Day 2 Programme

10:30 – 11:00      Tea Break

11:00 – 12:30

Breakout  
Room A

## Track 7: Biotech Sharing Session

### *Challenges and Opportunities For Biotechs to Conduct Clinical Trials in Singapore*

Biotech companies play an increasingly important role in therapeutics development in Singapore. This session will explore the unique challenges and opportunities faced by biotech companies conducting clinical trials in Singapore. From regulatory considerations to infrastructure development and funding, hear from speakers on how they are navigating the local clinical trial landscape.



**Dr Kwek Kon Yew**

Chief Medical Officer  
Hummingbird Bioscience



**Mr Ng Choon Peng**

CEO and Co-Founder  
ImmunoScape



**Dr Toh Han Chong**

Deputy CEO (Strategic Partnerships),  
National Cancer Centre, Singapore (NCCS)

Professor, Duke-NUS Medical School



**Dr Ho Wen Qi**

Therapeutics Lead  
ClavystBio

MODERATOR

11:00 – 12:30

Breakout  
Room B

## Track 8: Talent Development in Clinical Trials

### *Nurturing Excellence: Advancing Talent in Clinical Research*

This session will explore the significance of guiding emerging clinician scientists through mentorship, the essential functions fulfilled by clinical research coordinators (CRCs), and the pivotal role of a collaborative partnership between clinician scientists and CRCs in ensuring the efficient management of clinical trials.



**Ms Geraldine Lim**

Manager, Research Office – Clinical Trials  
& Research Unit (CTRU)  
Changi General Hospital



**A/Prof Joanne Ngeow**

Head (Cancer Genetics Service) &  
Senior Consultant (Division of Medical Oncology),  
National Cancer Centre Singapore

Associate Professor (Genomic Medicine),  
Lee Kong Chian School of Medicine,  
Nanyang Technological University (NTU)



**Dr Yeo Jing Ping**

Global Head, Project Operations  
Head, Transformation  
George Clinical



**Mr Kenneth Lee**

Vice President, Commercial Operations  
Parexel International

MODERATOR

# 31 July 2024, Wednesday • Day 2 Programme

12:30 – 14:00

Lunch & Networking

14:00 – 15:30

Main Plenary  
Room

## Track 9: Designing Trials for AI-Based Interventions / Diagnostics *Methodologies and Considerations for Trials Involving AI-Driven Technologies*

This session explores the critical aspects of conducting trials for artificial intelligence (AI) technologies. Gain insights on the challenges and considerations when designing a trial for AI technologies. Topics on ethical implications, regulatory compliance specific to AI interventions and diagnostics will also be discussed.



### Ms Karla Childers

Head, Bioethics-based Science &  
Technology Policy  
Office of the Chief Medical Officer  
Johnson & Johnson



### Dr Alex Zhavoronkov

Founder and CEO  
Insilico Medicine



### A/Prof Tan Cher Heng

Group Chief Research and Innovation Officer,  
National Healthcare Group (NHG)

Senior Consultant  
(Department of Diagnostic Radiology)  
and Assistant Chairman Medical Board  
(Clinical Research and Innovation),  
Tan Tock Seng Hospital  
(TTSH)

Assistant Dean (Clinical Research),  
Lee Kong Chian School of Medicine,  
Nanyang Technological University  
(NTU)



### A/Prof Liu Nan

Director,  
Duke-NUS AI + Medical Sciences Initiative  
(DAISI)

Associate Professor,  
Centre for Quantitative Medicine  
Duke-NUS Medical School

MODERATOR

# 31 July 2024, Wednesday • Day 2 Programme

15:30 – 17:00

Main Plenary  
Room

## Track 10: Data Powered Research

### *Innovations in Data-Driven Research: Shaping Tomorrow's Discoveries*

In a digital age, data-powered research is driving innovation and shaping future discoveries. Gain insights into the latest advancements in leveraging data to unlock new possibilities to advance research and transform healthcare.



#### Prof C. Michael Gibson

Professor of Medicine,  
Harvard

CEO,  
Baim Institute for Clinical Research  
(Formerly Harvard Clinical  
Research Institute)



#### Ms Koh Mingshi

Director, TRUST Office  
MOH Office for Healthcare  
Transformation (MOHT)



#### Prof Yeo Khung Keong

CEO & Senior Consultant,  
National Heart Centre Singapore  
(NHCS)

Deputy Group Chief Medical  
Informatics Officer (Research),  
SingHealth



#### Ms Yeoh Ying Ying

General Manager  
Roche Pharmaceuticals,  
Singapore

MODERATOR

17:00 – 17:15

Main Plenary  
Room

## Closing Address

### *The Future of Clinical Trials in Singapore*



#### Adj A/Prof Danny Soon

CEO, Consortium for Clinical Research  
and Innovation, Singapore (CRIS)

Executive Director, SCRI

17:15 – 18:30

## Networking Session

18:30

## End of Day 2

\*Please note that the programme may be subject to change without prior notice. Tracks 1-10 will comprise of a 45-min presentation by speakers followed by 45-min panel discussion.

# The Value Proposition of Clinical Trials in Singapore

July 2024

Clinical trials play a vital role within the healthcare ecosystem by promoting research, innovation, advancing clinician knowledge, and improving patient outcomes. This report delves into the benefits of conducting clinical trials and benchmarks Singapore's capabilities and performance against the global research landscape.

Outlining future trends and strategic recommendations, this report serves as a comprehensive guide for stakeholders in the clinical trials sector to understand gaps and opportunities in our ecosystem, allowing Singapore to enhance its global competitiveness in clinical trials.



**Adj A/Prof Danny Soon**

Chief Executive Officer,  
Consortium for Clinical Research  
and Innovation, Singapore (CRIS)

Executive Director,  
Singapore Clinical Research  
Institute (SCRI)

“

Due to our robust reputation for medical excellence, a competent regulatory body, connectivity, rule of law and highly trained workforce, Singapore has historically been a magnet in the region for clinical trials.

Other countries globally and regionally have taken notice of the incredible value and impact of clinical trials, and have made significant steps in building policy, infrastructure, and talent initiatives to attract sponsored clinical trials and research. Due to increased regional competition, Singapore's clinical trial numbers have stayed relatively flat over the last 5 years, and our share of global clinical trials has declined in comparison to regional centres.

Singapore is at a crossroad for clinical trials. SCRI has commissioned an in-depth report on the value proposition of clinical trials, a first for Singapore. We hope to provide a comprehensive overview of the current landscape of clinical trials in Singapore, exploring the strengths, opportunities, and challenges faced by the ecosystem. As Singapore continues to evolve as a global research hub, we are hopeful that the insights provided will be valuable for stakeholders looking to address challenges and build capabilities, so as to harness the full potential of clinical trials in shaping the future of healthcare and benefiting Singapore and Singaporeans.

”

# Singapore's Vibrant Clinical Trial Ecosystem

## Leading Biomedical Sciences Hub in Asia, for Global




Singapore's robust clinical trial ecosystem involves active participation from both:

**Public sector** — comprising hospital clusters, research institutions, funding organisations, and health and economic agencies.

**Private sector** — including industry sponsors and contract research organisations (CROs).

Clinical trials are critical in bringing novel treatments from bench to bedside.



Clinical trials have an important role in supporting life sciences and medical research

**Identify novel biomarkers and targets** allowing earlier diagnosis of diseases and unearthing new therapeutic targets

**Unearth new mechanisms / candidate treatments** through a better understanding of the disease

**Informing precision/personalised medicine** by identifying patient subgroups that may respond differently to treatments based on genetic, molecular or clinical characteristics

**Refine sophisticated research techniques** (e.g., innovative statistical analysis) which may lead to breakthroughs in other fields

# Singapore's Global Competitiveness

## Singapore has the right building blocks in place:



- Singapore's diverse multi-ethnic population facilitates research in Asian-specific diseases.
- Health Sciences Authority has a strong reputation and international networks to draw international collaborations.
- Centers of Excellence in oncology, ophthalmology, dermatology and cardiology where Key Opinion Leaders (KOLs) have built global reputations

## High-quality infrastructure and data ecosystem



- Strong existing data cohorts for oncology and cardiology.
- Data quality from local research and healthcare institutions is globally recognised.

## Conducive environment for early phase and innovative trials



- Offers suitable infrastructure and expertise for testing complex and innovative solutions.
- Globally recognised oncology research centres.


## Streamlined regulatory process for clinical trials




- Relatively fast regulatory approval of 30 days.

**Despite having the right building blocks, Singapore's share of global clinical trials has attenuated significantly, necessitating strategic reforms to regain its competitiveness.**

Singapore share of CT declined by nearly half over the past 10 years...



...driven by a sharp drop in industry led trials (ICT/IST)



# Unlocking Singapore's Potential For Clinical Trials

**Addressing administrative burdens and riding on Singapore's readiness to accommodate new modalities** in clinical trials positions Singapore well for future opportunities. The ambition is to **double the number of clinical trials** in the next 5 years via strategic recommendations:



## Ambition


**Double the number of clinical trials over the next 5 years, with >80% of drug trials being Industry-led trials** by aligning key operating metrics with leading peers (e.g., speed to trial etc.)

Where to play



- **Phase:** Early phase trials and regional network studies.
- **Focus:** Quality of clinical trials (rather than quantity), channelling funding and resources on a selected few trials aimed at optimising clinical practice and furthering therapeutics innovation

Maintain the current grant regime, but focus on awarding fewer IITs but with larger grants, and to provide more grants to recipients that promote collaboration with Singapore biotechs



- **Phase:** Greater share of Phase I & II; continuing to attract Phase III and IV CTs
- **TAs:** Singapore COEs with data availability for rapid patient recruitment in oncology, cardiology, dermatology, ophthalmology, etc. Healthy Ageing trials to leverage Healthier SG, ageing population, and strength of SG primary care network
- **Treatment modality:** New approaches to be proven and other novel trials (e.g., First-in-Human trials, emerging technologies such as CGT)
- **Trial modality:** Innovative trial designs, including decentralised trials, real world studies, digital/synthetic trials and network trials

How to win

### CAPABILITY

**Talent:**  
Enhance research talent pipeline, including development pathways for clinicians, trial nurses and CRCs, and clearer KPIs for clinicians to conduct CTs

**Data:**  
Move to pre-consented data collection; centralise data access across EMR (Epic), with a single entity for access and coordination

**Innovative trial design:**  
Develop 'Trials of the Future' COE to support stakeholders on innovative trial design (e.g., synthetic arms, DCT to lower costs, network trials to expand patient recruitment)

**Artificial intelligence:**  
Adopt AI solutions through the trial ecosystem

### OPERATING MODEL

**Governance:**  
Centralise trial coordination through a 'one-stop-shop' (including CRCs, ethics approvals, contracting, patient data for feasibility, recruiting and synthetic arms)

**Regulations:**  
Set up conditional/ expedited approval ahead of other regulatory agencies for locally conducted biotech trials; simplify data regulations to streamline data access

**Privatisation:**  
Expand privatisation of CTs across the value chain (e.g., private IRBs: Bellberry; private sites Lilly Centre)

**Incentives:**  
Introduce tier incentives for biotech startups based on size / number of assets (financial and in-kind); set up grants for local clinicians to work with biotechs

**The strategic recommendations coupled with proposed solutions can help set in motion a clinical trials flywheel, delivering significant healthcare and economic benefits to Singapore.**

*Figures are extracted from The Value Proposition of Clinical Trials in Singapore report.*



### Potential healthcare benefits (peak 2030)

- **~55K patients / year, who may not have therapeutic alternatives**, will be impacted through acute and chronic disease trials, greater progression-free survival and reduced mortality rates
- **~500k patients / year will benefit from improved overall health outcomes** in the form of better care from clinicians participating in CTs and who are more exposed to novel treatment and strict treatment protocols as a result



### Potential economic benefits (peak 2030)

- **~\$410M in GDP contribution / year**
- **~3.2K jobs from clinical trials / year**
- **~\$240-320M in cost savings / year** from drugs provided through clinical trials
- **Further ~1.2K jobs created** by supporting existing biotechs, and the 50-60 new biotechs the sector is targeting to import/create

*(Amounts indicated are in USD)*

For more information, please email SCRI at [contact@scri.cris.sg](mailto:contact@scri.cris.sg)





**DENGUE**  
ACADEMY


dengueacademy.sg

**Dengue Academy provides a personalized experience and access to the newest knowledge and medical resources on Dengue.**

## Access bite-sized Dengue information ON DEMAND!




**Article**



Stay up to date with recent news and research on Dengue



**Video**




Curated and in-house short videos on Dengue basics



**Courses**



Case studies by key experts on Dengue management



Scan QR code to visit  
**dengueacademy.sg**



© Copyright 2024 Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.  
8 Marina Boulevard, Marina Bay Financial Center, Tower 1, #05-02,  
Singapore 018981  
Tel: + 65 6808 9500      www.takeda.com

All trademarks are the property of their respective owners.  
All rights reserved.  
VV-MEDMAT-107789 JULY 2024

For Healthcare Professionals only.




## Achieving Clinical Trial Excellence With You

### Introducing CRInsight

-  Increased Operational Efficiency
-  Enhanced Agility
-  Analytics and Reporting


### Value-Driven Supply Chain Solutions

- Clinical Storage & Distribution
- Cold Chain Management
- Clinical Sourcing
- Secondary Packaging & Relabelling
- Regulatory Insights
- Project Management
- Returns & Destruction




Unlock success through collaboration.  
Connect with us at  
[CR\\_Marketing@zuelligpharma.com](mailto:CR_Marketing@zuelligpharma.com)


[www.zuelligpharma.com](http://www.zuelligpharma.com)




### Our experience



### ~100 projects



## YOUR TRUE CLINICAL TRIAL PARTNER IN ASIA-PACIFIC



### Contact us



CSI Medical Research



CSI Medical Research Pte Ltd



[www.csimedicalresearch.com](http://www.csimedicalresearch.com)





# The Promise of Clinical Trials: Transforming Tomorrow's Health

**SCRI Clinical Trials Symposium 2024**

**30 – 31 Jul 2024 • Raffles City Convention Centre**

Find out more at [www.scri-symposium.sg](http://www.scri-symposium.sg)

For enquiries, get in touch with us at  
[secretariat@scri-symposium.sg](mailto:secretariat@scri-symposium.sg)

